Lily Liu joined BeiGene in 2019 as Vice President, Head of Marketing for Greater China, with more than two decades of experience in the pharmaceutical industry. Prior to joining BeiGene, Dr. Liu was Vice President and Head of Specialty Care at Takeda in China, responsible for turning around the Enatone business and introducing the new product Ninlaro, which was added to China’s National Reimbursement Drug List within only five months of its approval. Previously, she served as Sales Head of Oncology, Immunology, and Rare Diseases for Pfizer, supporting Xalkori to become the number one product for Pfizer Oncology and successfully launching Xeljanz. Before Pfizer, Dr. Liu held a range of positions in marketing and market access at Janssen China and at their U.S. headquarters.

Dr. Liu has a degree in Pediatric Medicine from Capital Medical University.